Abstract
Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson’s disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
